Claims
- 1. A tricyclic compound represented by formula (I); ##STR13## wherein each of R.sup.1, R.sup.2, R.sup.3 and R.sup.4 independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9, R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6 alkyl); R.sup.5 represents hydrogen or C1-6 alkyl; each of R.sup.6, R.sup.7 and R.sup.8 independently represents hydrogen, C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen; X represents CH or N; Y.sup.1 -Y.sup.2 represents CH.sub.2 --O, CH.sub.2 --S(O).sub.n, (wherein n represents 0, 1, or 2), or CON(R.sup.14) (wherein R.sup.14 represents hydrogen or C1-6 alkyl) and Z represents oxygen or sulfur; or a pharmaceutically acceptable salt thereof.
- 2. The tricyclic compound as claimed in claim 1, wherein Y.sup.1 -Y.sup.2 represents CH.sub.2 --O.
- 3. The tricyclic compound as claimed in claim 2, wherein X represents CH.
- 4. The tricyclic compound as claimed in claim 3, wherein Z represents oxygen.
- 5. The tricyclic compound as claimed in claim 4, wherein R.sup.5 represents hydrogen.
- 6. The tricyclic compound as claimed in claim 5, wherein one of R.sup.6 R.sup.7 and R.sup.8 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen.
- 7. The tricyclic compound as claimed in claim 6, wherein one of R.sup.2 R.sup.3 and R.sup.4 represents C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9 R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6 alkyl).
- 8. The tricyclic compound as claimed in claim 7, wherein R.sup.1 represents hydrogen.
- 9. A compound according to claim 8, which is selected from the group consisting of 6,11-dihydro-N-(2,6-diisopropylphenyl)-2-methyldibenz[b,e]oxepin-11-carboxamide, 2-chloro-6,11-dihydro-N-(2,6-diisopropylphenyl)dibenz[b,e]oxepin-11-carboxamide, 2-bromo-6,11-dihydro-N-(2,6-diisopropylphenyl)dibenz[b,e]oxepin-11-carboxamide, 6,11-dihydro-N-(2,6-diisopropylphenyl)-2-methoxycarbonyldibenz[b,e]oxepin-11-carboxamide, 2-bromo-N-(2,6-dichlorophenyl)-6,11-dihydrodibenz[b,e]oxepin-11-carboxamide, 2-bromo-6,11-dihydro-N-(2,6-diisopropyl-4-methylthiophenyl)dibenz[b,e]oxepin-11-carboxamide, 6,11-dihydro-N-(2,6-diisopropylphenyl)-2,3-dimethyldibenz[b,e]oxepin-11-carboxamide, 6,11-dihydro-N-(2,6-diisopropylphenyl)-1,4-dimethyldibenz[b,e]oxepin-11-carboxamide, 6,11-dihydro-N-(2,6-diethylphenyl)-1,4-dimethyldibenz[b,e]oxepin-11-carboxamide, 2-bromo-6,11-dihydro-N-(2,6-diisopropylphenyl)-4-nitrodibenz[b,e]oxepin-11-carboxamide, 2-bromo-6, 11-dihydro-N-(2,6-diisopropylphenyl)-4-dimethylaminodibenz[b,e]oxepin-11-carboxamide hydrochloride, 2-bromo-6,11-dihydro-N-(2,6-diisopropylphenyl)-1,3-dimethyldibenz[b,e]oxepin-11-carboxamide, 2-bromo-N-(2,6-diethylphenyl)-6,11-dihydro-1,3-dimethyldibenz[b,e]oxepin-11-carboxamide, 4-chloro-6,11-dihydro-N-(2,6-diisopropylphenyl)-1,2-dimethyldibenz[b,e]oxepin-11-carboxamide, 6,11-dihydro-N-(2,6-diisopropylphenyl)-1,3-dimethyldibenz[b,e]oxepin-11-carboxamide, and 4-chloro-6,11-dihydro-N-(2,6-diisopropylphenyl)-1-methyldibenz[b,e]oxepin-11-carboxamide.
- 10. (-)-2-Bromo-6,11-dihydro-N-(2,6-diisopropylphenyl)dibenz[b,e]oxepin-11-carboxamide.
- 11. (+)-2-Bromo-6,11-dihydro-N-(2,6-diisopropylphenyl)dibenz[b,e]oxepin-11-carboxamide.
- 12. The tricyclic compound as claimed in claim 2, wherein X represents N.
- 13. The tricyclic compound as claimed in claim 12, wherein Z represents oxygen.
- 14. The tricyclic compound as claimed in claim 13, wherein R.sup.5 represents hydrogen.
- 15. The tricyclic compound as claimed in claim 14, wherein one of R.sup.6 R.sup.7 and R.sup.8 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen.
- 16. 2-bromo-5,11-dihydro-N-(2,6-diisopropylphenyl) benzoxepino[3,4-b]pyridine-5-carboxamide.
- 17. The tricyclic compound as claimed in claim 1, wherein Y.sup.1 -Y.sup.2 represents CH.sub.2 --S(O).sub.n, (wherein n represents 0, 1, or 2) or CON(R.sup.14) (wherein R.sup.14 represents hydrogen or C1-6 alkyl).
- 18. The tricyclic compound as claimed in claim 19, wherein X represents CH.
- 19. The tricyclic compound as claimed in claim 20, wherein Z represents oxygen.
- 20. The tricyclic compound as claimed in claim 21, wherein R.sup.5 represents hydrogen.
- 21. The tricyclic compound as claimed in claim 22, wherein one of R.sup.6 R.sup.7 and R.sup.8 represents C1-6 alkyl, hydroxy, C1-6 alkoxy, C1-6 alkanoyloxy, C1-6 alkylthio, thiocyanato or halogen.
- 22. A tricyclic compound represented by formula (IIa); ##STR14## wherein each of R.sup.la R.sup.2a R.sup.3a and R.sup.4a independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9a R.sup.10a CO.sub.2 R.sup.11a (wherein each of R.sup.9a R.sup.10a and R.sup.11a independently represents hydrogen or C1-6 alkyl) or CONR.sup.12a R.sup.13a (wherein each of R.sup.12a and R.sup.13a independently represents hydrogen or C1-6 alkyl); X represents CH or N.
- 23. A tricyclic compound represented by formula (VI); ##STR15## wherein each of R.sup.1a, R.sup.2a, R.sup.3a and R.sup.4a independently represents hydrogen, C1-6 alkyl, C1-6 alkoxy, C1-6 alkylthio, amino, C1-6 alkylamino, halogenated C1-6 alkyl, halogenated C1-6 alkoxy, halogen, nitro, cyano, carboxy, C1-6 alkoxycarbonyl, hydroxymethyl, CR.sup.9 R.sup.10 CO.sub.2 R.sup.11 (wherein each of R.sup.9 R.sup.10 and R.sup.11 independently represents hydrogen or C1-6 alkyl) or CONR.sup.12 R.sup.13 (wherein each of R.sup.12 and R.sup.13 independently represents hydrogen or C1-6 alkyl); X represents CH or N.
- 24. A pharmaceutical composition comprises pharmaceutically acceptable carrier and as active ingredient, effective amount of the compound as defined by claim 1.
Priority Claims (1)
Number |
Date |
Country |
Kind |
3-006589 |
Jan 1991 |
JPX |
|
Parent Case Info
This application is a continuation of U.S. patent application Ser. No. 823,456, filed Jan. 22, 1992, now abandoned.
US Referenced Citations (3)
Non-Patent Literature Citations (4)
Entry |
Chemical Abstract, vol. 91, No. 39211y, 1979, Abou-Gharbia et al, "Synthesis of tricyclic arylspiro comp. as potential antileukemic and anticonvulsant agents". |
J. Am. Chem. Soc. (1984) 106, 4175-80. |
Heterocycles, vol. 12, No. 5, (1979) 637-45. |
Chem. Abst., 98 (1983) 89198q. |
Continuations (1)
|
Number |
Date |
Country |
Parent |
823456 |
Jan 1992 |
|